THERANOSTICS 2016* , ,
Presentations this author is a contributor to:
Patient dosimetry assessment with the somatostatin receptor antagonist 68Ga-labelled OPS202 in the first clinical study of gastroenteropancreatic neuroendocrine tumors (GEP-NET) (#67)
8:30 AM
Uta Eberlein
Conference Breakfast: Moderated Poster Walk - Neuroendocrine tumours
Phase I/II open-label trial to evaluate the safety and preliminary efficacy of 177Lu-OPS201, a radiolabeled somatostatin receptor antagonist, in patients with somatostatin receptor-positive, progressive gastroenteropancreatic neuroendocrine tumors (#57)
8:30 AM
Rod Hicks
Conference Breakfast: Moderated Poster Walk - Neuroendocrine tumours